ACIU
AC Immune Ltd
2.60$
+0.8%
vs. previous close
Closing price · As of: Sep 30, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +163.8% | +95.3% | -15.4% | +48.9% | +52.2% | -20.2% | +9.5% | -28.9% | -1.7% | +26.3% | -33.1% | |
| – | +167.5% | +95.2% | -16.4% | +48.9% | +51.8% | -20.8% | -12.6% | -36.8% | -2.3% | +37.4% | -43.7% | |
| – | +2,214.6% | +98.9% | -18.3% | +25.8% | +23.7% | -16.9% | -48.9% | -61.6% | +148.5% | -53.8% | -26.0% | |
| – | +2,214.6% | +98.9% | -18.3% | +49.9% | +54.8% | -21.7% | -12.3% | -38.2% | -15.9% | +60.6% | -44.8% | |
| – | -98.8% | +344.9% | +164.4% | +10.4% | -65.9% | +13.7% | -38.7% | -58.2% | +3,587.7% | -92.7% | +21.7% | |
| – | +669.1% | -84.2% | -449.4% | – | – | – | – | – | -62,200,100.0% | – | – | |
| – | -9.5% | +124.9% | +110.1% | +41.3% | +85.7% | +7.6% | +21.0% | -12.0% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | +0.0% | +0.0% | +0.0% | +0.1% | |
| – | +30.2% | +54.4% | +10.6% | +24.8% | +41.6% | -13.2% | +26.7% | -42.5% | +30.8% | +435.1% | -7.7% | |
| – | +38.1% | +62.6% | -1.7% | +34.1% | +33.8% | -19.9% | +42.9% | -42.7% | +18.2% | +642.8% | -6.0% | |
| – | – | – | – | – | +229.5% | -59.5% | +28.7% | -3.9% | +22.6% | +52.7% | -17.0% | |
| – | +8.5% | +134.7% | -72.9% | +81.2% | -92.8% | +1,438.0% | -8.3% | -53.6% | +80.7% | +58.3% | -22.2% | |
| – | – | – | – | -52.9% | -100.0% | – | – | – | – | – | – | |
| – | +202.7% | +100.4% | -17.9% | +52.0% | +53.4% | -20.9% | +7.7% | -27.2% | -4.9% | -30.1% | -60.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | -9.6% | +14.5% | +7.8% | +15.0% | +1.1% | +4.2% | +11.5% | +1.4% | +17.7% | +1.1% |
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.